Dolapo (@_ottun) profile picture

MD| IM resident| @accintouch IM program| Aspiring 🫀

Georgia, USA
Joined August 2011
Photo by Dolapo (@_ottun)Photo by Dolapo (@_ottun)Photo by Dolapo (@_ottun)Photo by Dolapo (@_ottun)Photo by Dolapo (@_ottun)Photo by Dolapo (@_ottun)Photo by Dolapo (@_ottun)
7. OPTIMAL-DIABETES: In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg.
1
1
3
567
5. OPTIMAL-Stroke: Targeting a systolic BP of less than 120 mm Hg lowered the incidence of major cardiovascular events compared with targeting a systolic BP of less than 140 mm Hg in patients with previous ischemic stroke or transient ischemic attack.
1
1
3
594
4. REDUCE: Spironolactone-based blood pressure management significantly reduced home SBP compared with standard care at 3 months, with the reduction sustained at 6 months.
1
1
4
614
SYNCHRONIZE-CVOT results presented at #ScientificSessions26 In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.
3
8
1
11
1,667
ATTAIN-OSA results presented at #ScientificSessions26 Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.
2
8
1
26
2,582
Dolapo retweeted
Presented at #ScientificSessions26: In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-DIABETES trial results: nej.md/3UZYKCy @AHAScience
10
113
13
371
35,203
Nigeria are #U17WWC 2026 Champions! 🏆 🇳🇬
2,335
24,685
2,228
81,814
1,384,864
Dolapo retweeted
Presented at #ScientificSessions26: In patients with previous ischemic stroke or transient ischemic attack, a systolic blood-pressure target below 120 mm Hg was associated with fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-STROKE trial results: nej.md/3UasT1O @AHAScience
12
156
17
473
46,600
OPTIMAL-STROKE results presented at #ScientificSessions26 Targeting a systolic BP of less than 120 mm Hg lowered the incidence of major cardiovascular events compared with targeting a systolic BP of less than 140 mm Hg in patients with previous ischemic stroke or transient ischemic attack.
3
30
1
93
3,919
REDUCE results presented at #ScientificSessions26 Spironolactone-based blood pressure management significantly reduced home SBP compared with standard care at 3 months, with the reduction sustained at 6 months.
12
37
2,046
OCEANIC-STROKE results presented at #ScientificSessions26 In patients with recent non-cardioembolic ischemic stroke (NCIS) or high-risk TIA, asundexian reduced ischemic stroke with similar bleeding versus placebo across all FRS risk categories.
1
23
2
63
4,202
Dolapo retweeted
Presented at #ScientificSessions26: Among veterans with stable #CoronaryArteryDisease in extended follow-up of the COURAGE randomized trial, an initial strategy of #PercutaneousCoronaryIntervention plus optimal medical therapy did not reduce long-term risk of death or myocardial infarction vs optimal medical therapy alone. These findings do not support a routine strategy of elective upfront percutaneous coronary intervention to reduce long-term ischemic outcomes in this population. ja.ma/483lh4o @AHAMeetings @AHAScience
5
46
13
171
34,961
Dolapo retweeted
Presented at #ScientificSessions26: Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: nej.md/4AcZL9n @AHAScience
15
119
31
338
53,700
🧵/ Late breaking science results from #ScientificSessions26 will be posted to this thread at the time of presentation: ZEUS Lp(a) HORIZON OCEANIC-STROKE REDUCE OPTIMAL-Stroke STREAM Yoga-CaRe HF Trial SUPERIOR RACE-CARS ATTAIN-OSA SYNCHRONIZE-CVOT ⬇️ (bookmark this post)
4
27
2
126
13,390
ZEUS results presented at #ScientificSessions26. Lowering interleukin-6 levels with ziltivekimab did not lower the risk of cardiovascular events in patients with ASCVD, CKD, and cardiovascular inflammation compared to placebo.
8
1
30
2,297
Lp(a) HORIZON results presented at #ScientificSessions26 Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.
1
21
2
62
8,136
Dolapo retweeted
Be the first to read groundbreaking research that will be unveiled at #ScientificSessions26 across the American Heart Association Journals portfolio. Stay updated! ahajournals.org/ahasessions
1
10
1,104
Pregnancy and the year after birth is an important time for heart health. High blood pressure/preeclampsia, gestational diabetes, preterm birth and having a baby who is small for their gestational age can signal higher future cardiovascular risk. Timely diagnosis and follow-up care can turn these warning signs into opportunities for prevention. If you’re planning a pregnancy, the year beforehand is a good time to optimize heart health.
10
1
30
2,226
Heart Failure (HF) is now the No. 1 cause of cardiogenic shock, with mortality rising ~4x over 25 years. 👉 Slide 1: Key Stage D HF & shock stats 📊 Slide 2: Etiologies, HF subtypes & mortality 🔁 Share with your cardiology network! 🔗 Full report bit.ly/4iYFe2l
7
20
882
Our new review on bempedoic acid in statin intolerance is out! We explore evidence beyond CLEAR Outcomes and practical implementation. Grateful to learn from and collaborate with outstanding mentors @CarlosVergaraMD and @DrMichaelShapir. rdcu.be/HAWBqp62PBoa
2
3
1
22
1,441